炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1990万元。该股近5个交易日累计 上涨6.84%，主力资金合计净流入2649.53万元。 11月25日，金石亚药收涨6.22%，收盘价为12.81元，发生1笔大宗交易，合计成交量100万股，成交金额 1000万元。 责任编辑：小浪快报 第1笔成交价格为10.00元，成交100.00万股，成交金额1,000.00万元，溢价率为-21.94%，买方营业部为 国泰海通证券股份有限公司成都天府二街第二证券营业部，卖方营业部为国泰海通证券股份有限公司成 都天府二街第二证券营业部。 ...

A 天天基金 链接您与财富 美版材梳理 7 3 = 近期,随着各省份逐渐入冬,全国多地流感活动进入上升期。 机构表示,秋冬季流感高峰到来,有望带动流感疫苗、呼吸 道检测、流感用药、用药终端等细分方向的需求增长。 | 流感疫苗 | 检测服务 | | | --- | --- | --- | | 华兰疫苗 | 仁度生物 九安医疗 | | | 华兰生物 | 达安基因 | 万孚生物 | | 百克生物 | 圣湘生物 | 之江生物 | | 金迪克 | 东方生物 | 英诺特 | | 零售药店 | 流感用药 | | | 益丰药房 | 众生药业 | 华润三九 | | 漱玉平民 | 济川药业 | 特一药业 | | ##十 | NING W | 左阳斗左 | | 八学师 | NAREN THE SEY | | | --- | --- | --- | | -心草 | 方盛制药 | 金石亚药 | | 老百姓 | 健康元 | 自玄山 | | 健之佳 | 康恩贝 | HE | | 基金名称 | 近1年收益 | 成立来收益 | | --- | --- | --- | | 安信医药健康股票A | 51.37% | 49.70% | | 前海开源 ...

（文章来源：每日经济新闻） 每经AI快讯，11月24日，维生素板块盘初震荡走强，哈三联涨停，金石亚药涨超7%，广济药业涨超 6%，硕世生物、美农生物、亨迪药业跟涨。 ...

Group 1 - The company has multiple land holdings in Hainan Free Trade Zone, specifically in Haikou's Xiuying District, Jiangdong New District, and Meilan District [2] - The subsidiary, Hainan Asia Pharmaceutical Co., Ltd., owns approximately 48 acres of land for its "Pharmaceutical Valley" factory, which is equipped with advanced GMP-compliant production lines [2] - The company plans to enhance land utilization based on government planning and business development needs, aiming to maximize the investment value of the land [2]

Core Viewpoint - The stock of Shuoshi Biotechnology fell nearly 15% in the afternoon, with several other companies including Anglikang, Wanbangde, Kanglong Huacheng, Meidixi, Haoyuan Pharmaceutical, Jindike, and Jinshiyao also experiencing declines of over 5% [1] Company Performance - Shuoshi Biotechnology's stock decline of nearly 15% indicates significant market volatility [1] - Other companies in the sector, such as Anglikang and Wanbangde, also faced notable stock price drops, suggesting a broader trend affecting multiple firms [1] - The overall performance of the biotechnology sector appears to be under pressure, as indicated by the collective decline of several key players [1]

证券日报网讯金石亚药11月12日在互动平台回答投资者提问时表示，公司全资子公司海南亚洲制药股份 有限公司"快克清"磷酸奥司他韦胶囊已于去年10月获批，目前该产品销售已覆盖线下药店、线上平台， 方便患者便捷购药。该药品主要成分为磷酸奥司他韦，用于成人及儿童甲型和乙型流感的治疗和预防。 公司建立了健全高效的产销联动工作机制，能够根据市场销售情况实时调整产能，确保安全稳定的药品 供应。 （文章来源：证券日报） ...

金石亚药（300434.SZ）11月12日在投资者互动平台表示，公司全资子公司海南亚洲制药股份有限公 司"快克清"磷酸奥司他韦胶囊已于去年10月获批，目前该产品销售已覆盖线下药店、线上平台，方便患 者便捷购药。该药品主要成分为磷酸奥司他韦，用于成人及儿童甲型和乙型流感的治疗和预防。公司建 立了健全高效的产销联动工作机制，能够根据市场销售情况实时调整产能，确保安全稳定的药品供应。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问海南自贸区内是否有子公司生产奥司他韦这个药 物？网传"有药企7×24小时开足马力生产抗流感药物"，目前公司是否也有类似情形？ ...

Group 1 - Xinpeng Co., Ltd. provided a guarantee of 50 million yuan for its wholly-owned subsidiary, increasing the total guarantee amount to 1.258 billion yuan, which is 115.47% of the latest audited net assets [1] - Yonggui Electric's subsidiary signed a contract worth 15.8652 million yuan with CRRC Zhuzhou for supplying components for the Wuhan rail transit project [1] - Huada Technology secured project designations from multiple domestic automakers and battery companies, with a total expected sales amount of 2.9 billion yuan, over 80% of which is related to new energy projects [2] Group 2 - China National Machinery International signed a contract for a 5.71 billion yuan hospital construction project in Iraq, which represents 4.68% of the company's expected revenue for 2024 [3] - Fangzhi Technology plans to acquire 100% of Zhixiang Technology for 116 million yuan, focusing on AI-driven smart learning and sports solutions [4] - Demingli is in the early stages of planning a refinancing initiative, with no specific details on the amount or method yet [5] Group 3 - Hesheng Silicon Industry announced a shareholder's plan to reduce holdings by up to 2.29%, equating to 27.0706 million shares [7] - ST Lanhua's subsidiary plans to invest up to 65 million yuan in a juice beverage project in Chongqing [8] - Ruizhi Pharmaceutical developed an automated synthesis system for antibody-drug conjugates and nucleoside monomers in collaboration with East China Normal University [9] Group 4 - Lianying Laser's controlling shareholder intends to reduce holdings by up to 3 million shares, representing 0.88% of the total share capital [10] - Songyuan Safety's controlling shareholder plans to reduce holdings by up to 1% of the total share capital [12] - ST Kaixin's actual controller and major shareholders plan to transfer 5% of the company's shares at a price of 27.85 yuan per share [13] Group 5 - Bojun Technology plans to invest approximately 1 billion yuan in a new automotive parts production base, aiming for an annual capacity of 24 million sets [13] - Litong Electronics' controlling shareholder committed to not reducing holdings for 24 months, while other shareholders plan to reduce a total of 3.03% of shares [14] - Yaoyigou's actual controller intends to transfer 5.23% of shares to a company director at a price of 24 yuan per share [15] Group 6 - Baiwei Storage submitted H-share listing application materials to the China Securities Regulatory Commission [18] - Jinshi Yaya obtained a drug registration certificate for glucosamine sulfate capsules, which are suitable for osteoarthritis treatment [19] - Shangtai Technology plans to invest approximately 4.07 billion yuan in a lithium-ion battery anode material project [19] Group 7 - Xinlitai's shareholder plans to reduce holdings by up to 800,000 shares, representing 0.07% of the total share capital [20] - Yunnan Baiyao elected Zhang Wenxue as the chairman of the board for a three-year term [21] - Huading Co., Ltd. announced that two shareholders plan to reduce their holdings by up to 3% of the total share capital [23] Group 8 - Jiahua Technology's shareholder plans to reduce holdings by up to 0.65% of the total share capital [25]

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

Core Viewpoint - The company has received approval for its glucosamine sulfate capsule from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [2]. Group 1 - The company, Sichuan Jinshi Asia Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has been granted a drug registration certificate for glucosamine sulfate capsules [2].